Solstein Capital’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-34
Closed -$12.2K – 406
2026
Q2
$12.2K Hold
34
– – ﹤0.01% 321
2026
Q1
$8.52K Hold
34
– – ﹤0.01% 341
2025
Q4
$9.36K Hold
34
– – ﹤0.01% 338
2025
Q3
$8.92K Hold
34
– – ﹤0.01% 341
2025
Q2
$7.44K Hold
34
– – ﹤0.01% 361
2025
Q1
$7.61K Hold
34
– – ﹤0.01% 252
2024
Q4
$11.1K Hold
34
– – 0.01% 234
2024
Q3
$10.2K Hold
34
– – 0.01% 242
2024
Q2
$11.2K Hold
34
– – 0.01% 232
2024
Q1
$13.5K Hold
34
– – 0.01% 222
2023
Q4
$12K Hold
34
– – 0.01% 225
2023
Q3
$12.8K Hold
34
– – 0.01% 209
2023
Q2
$13K Hold
34
– – 0.01% 214
2023
Q1
$11.8K Hold
34
– – 0.01% 199
2022
Q4
$8K Hold
34
– – 0.01% 222
2022
Q3
$8K Hold
34
– – 0.01% 240
2022
Q2
$10K Hold
34
– – 0.01% 261
2022
Q1
$14K Hold
34
– – 0.01% 273
2021
Q4
$16K Hold
34
– – 0.01% 289
2021
Q3
$14K Hold
34
– – 0.01% 326
2021
Q2
$12K Hold
34
– – 0.01% 318
2021
Q1
$10K Buy
+34
New +$9.7K 0.01% 298
2020
Q2
– Sell
-158
Closed -$24K – 305
2020
Q1
$24K Hold
158
– – 0.09% 129
2019
Q4
$24K Buy
+158
New +$23K 0.05% 170

Other funds holding WST

Solstein Capital's WST Position: Q3 2026 in Review

Solstein Capital sold out of West Pharmaceutical (WST) in Q3 2026, closing a stake of 34 shares — an estimated $12.2K sold.

Solstein Capital first reported a position in WST in Q4 2019 and held it in 24 quarters. The position peaked at $24K in Q1 2020. 878 funds tracked by Wall St. Rank hold WST as of Q3 2026.

  • Solstein Capital reported no remaining West Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Solstein Capital sold 34 West Pharmaceutical shares in Q3 2026, an estimated $12.2K.
  • Solstein Capital first reported a position in West Pharmaceutical in Q4 2019 and held it in 24 quarters.
  • Solstein Capital's West Pharmaceutical position peaked at $24K in Q1 2020.
  • 878 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2026.

Based on Solstein Capital's 13F filing for Q3 2026, filed 2 Nov 2026.